ZVSA (ZyVersa Therapeutics) OCF Yield %: -273.76 (As of Jun. 28, 2026)


ZVSA ZyVersa Therapeutics Inc ZVSA
31 GF Score
Price $0.19
! 1 Warning Sign
View Full Analysis

What is ZyVersa Therapeutics OCF Yield %?

ZyVersa Therapeutics ZVSA +16.81% 31 OCF Yield % is -273.76 as of Jun. 28, 2026. GuruFocus rates ZVSA with a GF Score™ of 31/100. The stock has 1 warning sign investors should review. Among 1,417 Biotechnology companies, ZyVersa Therapeutics ranks worse than 96.75% on this metric.

OCF Yield % is calculated as Cash Flow from Operations divided by Market Capitalization. It is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

As of today, ZyVersa Therapeutics's Trailing 12-Month Cash Flow from Operations is $-4.14 Mil, and Market Cap is $1.51 Mil. Therefore, ZyVersa Therapeutics's OCF Yield % for today is -273.76%.

The historical rank and industry rank for ZyVersa Therapeutics's OCF Yield % or its related term are showing as below:

ZVSA' s OCF Yield % Range Over the Past 10 Years
Min: -273.76   Med: 0   Max: -273.76
Current: -273.76


During the past 6 years, the highest OCF Yield % of ZyVersa Therapeutics was -273.76%. The lowest was -273.76%. And the median was %.

ZVSA's OCF Yield % is ranked worse than
96.75% of 1417 companies
in the Biotechnology industry
Industry Median: -8.4 vs ZVSA: -273.76

ZyVersa Therapeutics's OCF Margin % for the quarter that ended in Mar. 2026 was %.


ZyVersa Therapeutics OCF Yield % Explanation

Similar to Earnings Yield %, OCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high operating cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.


ZyVersa Therapeutics OCF Yield % Related Terms


ZyVersa Therapeutics OCF Yield % Historical Data

* Premium members only.

The historical data trend for ZyVersa Therapeutics's OCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ZyVersa Therapeutics OCF Yield % Chart

ZyVersa Therapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Yield %
Get a 7-Day Free Trial 0.00 -10.46 -239.26 -282.87 -472.81

ZyVersa Therapeutics Quarterly Data
Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -439.09 -184.51 -472.90 -153.10 -197.38

ZVSA vs AXIM, ISCO, HEPA: OCF Yield % Comparison

For the Biotechnology subindustry, ZyVersa Therapeutics's OCF Yield %, along with its competitors' market caps and OCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ZyVersa Therapeutics OCF Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ZyVersa Therapeutics's OCF Yield % distribution charts can be found below:

* The bar in red indicates where ZyVersa Therapeutics's OCF Yield % falls into.


ZVSA
31GF Score
ZyVersa Therapeutics Inc ZVSA
OCF Yield % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ZyVersa Therapeutics OCF Yield % Calculation

OCF Yield % is a financial solvency ratio that compares the operating cash flow a company is expected to earn against its market value.

ZyVersa Therapeutics's OCF Yield % for the fiscal year that ended in Dec. 2025 is calculated as

OCF Yield %=Cash Flow from Operations / Market Cap
=-5.114 / 1.0816256
=-472.81%

ZyVersa Therapeutics's annualized OCF Yield % for the quarter that ended in Mar. 2026 is calculated as

OCF Yield %=Cash Flow from Operations * Annualized Factor / Market Cap
=-0.799 * 4 / 1.6192
=-197.38%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Yield % →
What does a OCF Yield % of -273.76 mean?
ZyVersa Therapeutics (ZVSA) has a OCF Yield % of -273.76 as of Jun. 28, 2026. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on ZyVersa Therapeutics and its competitors. According to the industry distribution chart, ZyVersa Therapeutics ranks #1371 out of 1417 companies in the Biotechnology industry, placing it in the top 96.8%.
Is ZyVersa Therapeutics' OCF Yield % too high?
ZyVersa Therapeutics' current OCF Yield % is -273.76. Based on the distribution chart, ZyVersa Therapeutics ranks #1371 out of 1417 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ZyVersa Therapeutics has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does ZyVersa Therapeutics' OCF Yield % compare to AXIM and ISCO?
According to the Biotechnology industry distribution chart, ZyVersa Therapeutics ranks #1371 out of 1417 companies for OCF Yield %. This places ZyVersa Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Yield % for a Biotechnology company?
A good OCF Yield % depends on the Biotechnology industry context. However, OCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Yield % mean?
A high OCF Yield % can signal that a stock is expensive relative to its fundamentals. OCF Yield is calculated as Cash Flow from Operations divided by Market Capitalization. View historical data on ZyVersa Therapeutics and its competitors. ZyVersa Therapeutics's current OCF Yield % is -273.76. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ZyVersa Therapeutics stock overvalued right now?
ZyVersa Therapeutics (ZVSA) has a current OCF Yield % of -273.76. The current OCF Yield % is -273.76. ZyVersa Therapeutics' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Yield % calculated?
OCF Yield % is calculated from a company's financial statements. For ZyVersa Therapeutics (ZVSA), the current OCF Yield % is -273.76 as of Jun. 28, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ZyVersa Therapeutics Business Description

Address 2200 North Commerce Parkway, Suite 208, Weston, FL, USA, 33326
ZyVersa Therapeutics Inc is a clinical-stage biopharmaceutical company leveraging proprietary technologies to develop drugs for patients with chronic renal or inflammatory diseases with high unmet medical needs. The company has two proprietary globally licensed drug development platforms which are Cholesterol Efflux MediatorTM, VAR 200 (2-hydroxypropyl-beta-cyclodextrin) is an injectable drug in clinical development for the treatment of renal diseases. and IC 100 is a monoclonal antibody inflammasome ASC inhibitor in preclinical development for the treatment of inflammatory conditions.
31GF Score

Get the complete analysis for ZVSA

OCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.19
Price